{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.66","value":"33.38"}]}],"title":"2 hours post dose administration at Week 2 (n:55)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.96","value":"30.89"}]}],"title":"2 hours post dose administration at Week 4 (n:49)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.10","value":"34.48"}]}],"title":"2 hours post dose administration at Week 12 (n:56)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.25","value":"39.27"}]}],"title":"2 hours post dose administration at Week 24 (n:50)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.45","value":"33.20"}]}],"title":"2 hours post dose administration at Week 48 (n:14)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"}],"units":"Participants"}],"description":"C2h values collected 1-3 hours after dose administration on the same study day, at steady state, and patient did not vomit between taking previous dose and blood collection. Samples collected during the first 4 days of dosing will be excluded from all analyses.","dispersionType":"Standard Deviation","groups":[{"description":"Study drug was given by continuous oral daily dosing of two 5 mg tablets.","id":"OG000","title":"Everolimus Randomized (Core Period)"}],"paramType":"MEAN","populationDescription":"The analysis was performed in the Safety Set population for patients treated only with Everolimus and with a confirmed PK sample.","reportingStatus":"POSTED","timeFrame":"2 hours post-dose administration at Weeks 2, 4, 12, 24, 48","title":"Everolimus Blood Concentrations (C2h) at 2 Hours Post-dose","type":"SECONDARY","unitOfMeasure":"ng/mL"}